GlassScriptPhysician profile
Eric S Sztejman
NPI 1255386355
$5,659.65
in general payments reported to CMS, 2019-2025
35 companies · $2,392 in 2025
The $2,392 reported for 2025 was more than what 88% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28.54 · 2020: $884 · 2021: $11.58 · 2022: $536 · 2023: $210 · 2024: $1,598 · 2025: $2,392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,199.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,768.65 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $954.27 | 2020-2025 | Tezspire, Fasenra, Airsupra |
| Mylan Specialty L.P. | $870.00 | 2020 | |
| Harmony Biosciences LLC | $346.43 | 2022-2025 | |
| Verona Pharma, INC. | $182.65 | 2025 | Ohtuvayre |
| Insmed, INC. | $172.57 | 2024-2025 | Arikayce, Brinsupri |
| Regeneron Healthcare Solutions, INC. | $144.02 | 2023-2025 | Dupixent |
| Medtronic, INC. | $138.00 | 2025 | |
| Jazz Pharmaceuticals INC. | $120.95 | 2023-2025 | |
| Pulmonx Corporation | $110.23 | 2022 | |
| Grifols USA, LLC | $109.99 | 2024-2025 | Prolastin-C Liquid |
| Genzyme Corporation | $101.81 | 2022-2025 | |
| Inari Medical, INC. | $91.54 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Amgen INC. | $73.83 | 2023-2025 | Tezspire |
| Philips North America LLC | $61.45 | 2023-2025 | Vest Therapy Und |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.75 | 2024 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Ani Pharmaceuticals, INC. | $43.18 | 2025 | Purified Cortrophin Gel |
| Avadel Cns Pharmaceuticals, LLC | $36.80 | 2024 | Lumryz |
| Genentech USA, INC. | $34.15 | 2024 | Xolair |
| Ceribell, INC. | $26.07 | 2025 | Pocket Eeg Device |
| Resmed Corp | $19.13 | 2024 | |
| Abiomed | $19.06 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.67 | 2025 | Aralast |
| Viatris Specialty LLC | $18.57 | 2025 | Yupelri |
| Electromed, INC. | $18.37 | 2023 | Smartvest |
| United Therapeutics Corporation | $18.27 | 2025 | Tyvaso |
| Abbvie INC. | $18.06 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.00 | 2024 | |
| Inspire Medical Systems, INC. | $15.73 | 2024 | Inspire |
| Axsome Therapeutics, INC. | $14.99 | 2024 | Sunosi |
| Merck Sharp & Dohme LLC | $14.39 | 2023 | |
| Novartis Pharmaceuticals Corporation | $14.05 | 2019 | |
| Lilly USA, LLC | $14.02 | 2025 | Zepbound |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Sztejman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.